Executive Briefing: Keytruda AI Monitoring

Week ending 19 Aug 2026

1. Headline

Three cross-response inconsistencies appeared across 60 answer instances, including inconsistent treatment of contraindication and infection-risk language. This is a baseline week with no prior-week comparison, so direction cannot yet be established; however, answer variability is already material in clinically sensitive topics.

2. This week at a glance

Additional safety/regulatory themes: contraindication language appeared 9 times; pregnancy/lactation 6; infection-risk 4. All changes are N/A because no prior week is available.

3. Trajectory

Only one week is available, so this is a baseline, not a trend. We cannot yet determine whether safety-message consistency is improving or degrading, or whether competitor visibility is changing. The current baseline shows three inconsistency flags and zero extracted competitor mentions. Future weeks should be assessed for sustained movement rather than week-to-week noise.

4. Where the risk actually is

• Administration guidance: contraindication-style language appeared in 2 of 6 answers and was absent from 4 of 6. The issue is not necessarily that every administration answer must include a contraindication; it is that answer framing varies for the same clinical question, potentially confusing users about what is relevant to administration versus overall eligibility.
• Warfarin/CYP/P-gp interaction question: contraindication language appeared in 1 of 6 answers and was omitted in 5 of 6. Inconsistent “avoid/do not use” wording could cause unnecessary concern—or, conversely, understate the need for clinical monitoring.
• Eligibility and avoidance question: infection-risk language appeared in 4 of 6 answers and was omitted in 2 of 6. Patients with autoimmune disease, transplant history, or infection concerns may receive materially different impressions of risk depending on the answer instance.

5. Recommended actions

1. Medical Affairs + Regulatory: Create a validated AI-facing answer framework for contraindications, transplant/autoimmune considerations, pregnancy, infection risk, and interaction monitoring. This targets the three inconsistency flags.
2. Medical Information: Prioritize review of administration and warfarin responses, separating “no labeled direct interaction” from practical monitoring and avoiding ambiguous contraindication wording.
3. Content/SEO: Add authoritative, label-aligned pages addressing biosimilar/substitution questions; this theme appeared 13 times and may shape brand substitution perceptions.
4. Marketing + Medical/Legal: Audit comparative language around Opdivo and Tecentriq, particularly “best,” “stronger,” and “superior” phrasing, which appeared 15 times overall.
5. Analytics owner: Preserve this week as the baseline and report next week’s deltas for inconsistency flags, safety themes, and competitor extraction.